Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMTNQB0)

• Drug Name: CC-486 Drug Info
• Synonyms: AG-14361; AG14361; 328543-09-5; UNII-48N0U0K50I; AG 14361; CHEMBL65892; 48N0U0K50I; Imidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one, 2-[4-[(dimethylamino)methyl]phenyl]-5,6-dihydro-; AG-014361; 1-(4-((dimethylamino)methyl)phenyl)-8,9-dihydro-2,7,9a-triazabenzo[cd]azulen-6(7H)-one; Imidazo(4,5,1-jk)(1,4)benzodiazepin-7(4H)-one, 2-(4-((dimethylamino)methyl)phenyl)-5,6-dihydro-; 2-[4-[(Dimethylamino)methyl]phenyl]-5,6-dihydroimidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one; SMR000486393; MLS006011157; MLS001065917; Nucleoside analogue

Indication

Disease Entry	ICD 11	Status	REF
Acute myeloid leukaemia	2A60	Phase 3	[1]
Myelodysplastic syndrome	2A37	Phase 3	[2]
Diffuse large B-cell lymphoma	2A81	Phase 1	[1]

• Cross-matching ID:
  PubChem CID: 9840076
  ChEBI ID: CHEBI:92015
  CAS Number: CAS 328543-09-5
  TTD Drug ID: DMTNQB0

Molecule-Related Drug Atlas

Drug(s) Targeting Poly [ADP-ribose] polymerase 1 (PARP1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Nicotinamide	DMUPE07	Acne vulgaris	ED80	Approved	[5]
KU-0058948	DMSA4HZ	Ovarian cancer	2C73	Approved	[6]
Niraparib Tosylate	DMLPSWQ	Fallopian tube cancer	2C74	Approved	[7]
Nicaraven	DMFBNA3	Cerebrovascular disease	8B2Z	Phase 3	[8]
PMID27841036-Compound-37	DM0OVZ2	Ovarian cancer	2C73	Phase 2	[9]
Stenoparib	DMKVBL8	Ovarian cancer	2C73	Phase 2	[10]
AG140699	DMA9FKY	Melanoma	2C30	Phase 2	[11]
AZD5305	DMW9R1C	Prostate cancer	2C82.0	Phase 2	[12]
AMXI 5001	DMR9H6B	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[13]
NMS-03305293	DM2XIRW	Solid tumour/cancer	2A00-2F9Z	Phase 1	[14]

Drug(s) Targeting DNA [cytosine-5]-methyltransferase 1 (DNMT1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
S-110	DMXY34J	Acute myeloid leukaemia	2A60	Phase 3	[15]
SGI110	DM1NQDW	Acute myeloid leukaemia	2A60	Phase 3	[16]
Guadecitabine	DM9Y3EG	Myelodysplastic syndrome	2A37	Phase 3	[1]
Palifosfamide	DMMIYZ7	Soft tissue sarcoma	2B57	Phase 2	[17]
RX-3117	DME8ARP	Bladder cancer	2C94	Phase 2	[18]
Antroquinonol	DMRGQVZ	Non-small-cell lung cancer	2C25.Y	Phase 2	[19]
GSK4172239	DM930LE	Sickle-cell disorder	3A51	Phase 1	[20]
PMID27376512-Compound-MTC-424	DMGNRZU	N. A.	N. A.	Patented	[21]
PMID27376512-Compound-MTC-427	DMWXEZD	N. A.	N. A.	Patented	[21]
PMID27376512-Compound-MTC-422	DM1MVQD	N. A.	N. A.	Patented	[21]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
DNA [cytosine-5]-methyltransferase 1 (DNMT1)	TT6S2FE	DNMT1_HUMAN	Inhibitor	[3]
Poly [ADP-ribose] polymerase 1 (PARP1)	TTVDSZ0	PARP1_HUMAN	Inhibitor	[4]

References

• [1] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [2] J Clin Oncol 33, 2015 (suppl, abstr TPS7097).
• [3] Efficacy and safety of extended dosing schedules of CC-486 (oral azacitidine) in patients with lower-risk myelodysplastic syndromes. Leukemia. 2016 Apr;30(4):889-96.
• [4] Tricyclic benzimidazoles as potent poly(ADP-ribose) polymerase-1 inhibitors. J Med Chem. 2003 Jan 16;46(2):210-3.
• [5] beta-1,2,3-Triazolyl-nucleosides as nicotinamide riboside mimics. Nucleosides Nucleotides Nucleic Acids. 2009 Mar;28(3):238-59.
• [6] Structural basis for inhibitor specificity in human poly(ADP-ribose) polymerase-3. J Med Chem. 2009 May 14;52(9):3108-11.
• [7] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [8] Inhibition of poly (ADP-ribose) polymerase as a protective effect of nicaraven in ionizing radiation- and ara-C-induced cell death. Anticancer Res. 2006 Sep-Oct;26(5A):3421-7.
• [9] PARP inhibitors as antitumor agents: a patent update (2013-2015).Expert Opin Ther Pat. 2017 Mar;27(3):363-382.
• [10] Clinical pipeline report, company report or official report of Allarity Therapeutics.
• [11] Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors. Nat Rev Drug Discov. 2005 May;4(5):421-40.
• [12] Preclinical Characterization of AZD5305, A Next-Generation, Highly Selective PARP1 Inhibitor and Trapper. Clin Cancer Res. 2022 Nov 1;28(21):4724-4736.
• [13] AMXI-5001, a novel dual parp1/2 and microtubule polymerization inhibitor for the treatment of human cancers. Am J Cancer Res. 2020 Aug 1;10(8):2649-2676.
• [14] NMS-P293, a PARP-1 selective inhibitor with no trapping activity and high CNS penetration, possesses potent in vivo efficacy and represents a novel therapeutic option for brain localized metastases and glioblastoma. Cancer Res 2018;78(13 Suppl):Abstract nr 4843.
• [15] S110, a 5-Aza-2'-deoxycytidine-containing dinucleotide, is an effective DNA methylation inhibitor in vivo and can reduce tumor growth. Mol Cancer Ther. 2010 May;9(5):1443-50.
• [16] Immunomodulatory action of the DNA methyltransferase inhibitor SGI-110 in epithelial ovarian cancer cells and xenografts. Epigenetics. 2015;10(3):237-46.
• [17] Anticancer activity of stabilized palifosfamide in vivo: schedule effects, oral bioavailability, and enhanced activity with docetaxel and doxorubicin. Anticancer Drugs. 2012 Feb;23(2):173-84.
• [18] Metabolism, mechanism of action and sensitivity profile of fluorocyclopentenylcytosine (RX-3117; TV-1360). Invest New Drugs. 2013 Dec;31(6):1444-57.
• [19] Antroquinonol D, isolated from Antrodia camphorata, with DNA demethylation and anticancer potential. J Agric Food Chem. 2014 Jun 18;62(24):5625-35.
• [20] Clinical pipeline report, company report or official report of GlaxoSmithKline
• [21] DNA methyltransferase inhibitors: an updated patent review (2012-2015).Expert Opin Ther Pat. 2016 Sep;26(9):1017-30.